Publications by authors named "Sonya Cyr"

Claim this Profile
D
Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naïve Patients with Chronic Spontaneous Urticaria.
Ana M Giménez-Arnau, Thomas B Casale, Gil Yosipovitch, Luis Felipe Ensina, Naoko Inomata, Sonya L Cyr

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Onset of Atopic Comorbidities Relative to Atopic Dermatitis in Pediatric Patients.
Yael A Leshem, Clara Weil, William W Busse, Lisa A Beck, Gabriel Chodick, Sonya L Cyr

Dermatol Ther (Heidelb)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Reduces Pruritus in Clinically Distinct Dermatologic Diseases: Data from Clinical Trials on Atopic Dermatitis, Prurigo Nodularis, and Chronic Spontaneous Urticaria.
Gil Yosipovitch, Brian S Kim, John Y Koo, Zhen Chen, Simmi Wiggins, Sonya L Cyr

Dermatol Ther (Heidelb)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Infection Rates With Long-Term Dupilumab Treatment in Patients Aged 6 Months to 5 Years: An Open-Label Extension Study.
Amy S Paller, Michele Ramien, Michael J Cork, Eric L Simpson, Lara Wine Lee, Sonya L Cyr

Pediatr Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroimmune interplay during type 2 inflammation: Symptoms, mechanisms, and therapeutic targets in atopic diseases.
Brian Kim, Marc E Rothenberg, Xin Sun, Claus Bachert, David Artis, Sonya Cyr

J Allergy Clin Immunol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Amy S Paller, Elaine C Siegfried, Michael J Cork, Peter D Arkwright, Lawrence F Eichenfield, Sonya L Cyr

Paediatr Drugs· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis.
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Randy Prescilla, Sumeet Uppal, Sonya L Cyr

Pediatr Dermatol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Elaine C Siegfried, Michael J Cork, Norito Katoh, Haixin Zhang, Chien-Chia Chuang, Sonya L Cyr

Am J Clin Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Andrew Blauvelt, Andreas Wollenberg, Lawrence F Eichenfield, Haixin Zhang, Debra Sierka, Sonya L Cyr

Adv Ther· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current and Emerging Strategies to Inhibit Type 2 Inflammation in Atopic Dermatitis.
El-Bdaoui Haddad, Sonya L Cyr, Kazuhiko Arima, Robert A McDonald, Noah A Levit

Dermatol Ther (Heidelb)· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Amy S Paller, Lisa A Beck, Andrew Blauvelt, Elaine C Siegfried, Michael J Cork, Sonya L Cyr

Pediatr Dermatol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials.
Christopher Griffiths, Marjolein de Bruin-Weller, Mette Deleuran, Maria Concetta Fargnoli, Delphine Staumont-Sallé, Sonya L Cyr

Dermatol Ther (Heidelb)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hospital Cost of Staphylococcal Infection after Cardiothoracic or Orthopedic Operations in France: A Retrospective Database Analysis.
Aurélie Schmidt, Stève Bénard, Sonya Cyr

Surg Infect (Larchmt)· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
Yan Huang, Sonya L Cyr, David S Burt, Robert Anderson

J Clin Virol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
Sonya L Cyr, Isabelle Angers, Loic Guillot, Ioana Stoica-Popescu, Michèle Lussier

Vaccine· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
Sonya L Cyr, Taff Jones, Ioana Stoica-Popescu, Angela Brewer, Sophie Chabot

Vaccine· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces.
Sophie M Chabot, Tyler S Chernin, May Shawi, Jessica Wagner, Stephanie Farrant, Sonya Cyr

Vaccine· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
Sonya L Cyr, Taff Jones, Ioana Stoica-Popescu, David Burt, Brian J Ward

Vaccine· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection.
Taff Jones, Jeffrey J Adamovicz, Sonya L Cyr, Chris R Bolt, Nathalie Bellerose

Vaccine· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.
Sophie Chabot, Angela Brewer, George Lowell, Martin Plante, Sonya Cyr

Vaccine· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protollin: a novel adjuvant for intranasal vaccines.
Taff Jones, Sonya Cyr, Francine Allard, Nathalie Bellerose, George H Lowell

Vaccine· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.
Taff Jones, Francine Allard, Sonya L Cyr, Steven P Tran, Martin Plante

Vaccine· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucosal immunology - 11th International Congress.
Sonya Cyr

IDrugs· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis